These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 7762650)

  • 21. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
    Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
    J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets.
    Siegel EG; Schulze A; Schmidt WE; Creutzfeldt W
    Eur J Clin Invest; 1992 Mar; 22(3):154-7. PubMed ID: 1582439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA; Siemsglüss J; Orskov C; Holst JJ
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of glucagon-like peptide-1 on insulin secretion.
    Shima K; Hirota M; Ohboshi C
    Regul Pept; 1988 Aug; 22(3):245-52. PubMed ID: 3051138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
    Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
    Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
    Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic stimulatory effect of glucagon-like peptide-1 (7-36) amide and glucose-dependent insulin-releasing polypeptide on the endocrine rat pancreas.
    Fehmann HC; Göke B; Göke R; Trautmann ME; Arnold R
    FEBS Lett; 1989 Jul; 252(1-2):109-12. PubMed ID: 2668027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice.
    Pacini G; Thomaseth K; Ahrén B
    Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
    Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
    Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GIP(3-30)NH
    Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.
    Roberge JN; Brubaker PL
    Endocrinology; 1993 Jul; 133(1):233-40. PubMed ID: 8319572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
    Drewes C; Nauck MA; Horn R; Holst J; Schmiegel W; Brabant G
    Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.
    Orskov C; Wettergren A; Holst JJ
    Scand J Gastroenterol; 1996 Jul; 31(7):665-70. PubMed ID: 8819215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.